Pangaea Oncology, S.A. (BME:PANG)

Spain · Delayed Price · Currency is EUR

1.640

-0.080 (-4.65%)

Apr 28, 2026, 4:00 PM CET

-1.20% (1Y)

Market Cap	59.26M
Revenue (ttm)	14.35M
Net Income (ttm)	-5.34M
Shares Out	36.13M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,098
Average Volume	1,224
Open	1.640
Previous Close	1.720
Day's Range	1.640 - 1.640
52-Week Range	1.630 - 1.750
Beta	-0.02
RSI	61.15
Earnings Date	May 5, 2026

About Pangaea Oncology

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx p... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2006

Employees 159

Stock Exchange Madrid Stock Exchange

Ticker Symbol PANG

Full Company Profile

Financial Performance

In 2023, Pangaea Oncology's revenue was 9.95 million, an increase of 49.12% compared to the previous year's 6.68 million. Losses were -4.66 million, 71.7% more than in 2022.

Financial Statements

News

There is no news available yet.